Home
Clinical Resources Search
PQI: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

Download PQI pdf 0.16MB

Last Updated: November 14, 2023

By: Yonatan Resnick, PharmD

About this PQI

This PQI will discuss the rationale for the clinical use of the oral DNMT/CDA inhibitor decitabine/cedazuridine (DEC-C) for the management of intermediate-1, intermediate-2, and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

More About This PQI

PQI in Action Articles:

Decitabine_Inqovi_hematological_malignancies pdf 3.04MB

PQI in Action Articles:

Decitabine_cedazuridine_Inqovi_hematological pdf 2.59MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Chronic Myelomonocytic Leukemia (CMML) Hematological Malignancies Myelodysplastic Syndrome (MDS) Myeloproliferative Neoplasm cedazuridine Decitabine Inqovi

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

About this PQI

More About This PQI

PQI in Action Articles:

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Ponatinib (Iclusig®) Patient Management

PQI Podcast S7 Ep 8: Sickle Cell Disease Insights

PQI: Imetelstat (RYTELO®) in the treatment of low-to-intermediate-1-risk myelodysplastic syndromes (MDS)

PQI: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

PQI in Action: Ropeginterferon alfa-2b-njft (BESREMi®) Use in Polycythemia Vera

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings